Published ahead of print on October 19, 2006, doi:10.1164/rccm.200605-713OC
American Journal of Respiratory and Critical Care Medicine Vol 175. pp. 250-255, (2007)
© 2007 American Thoracic Society
doi: 10.1164/rccm.200605-713OC
C-reactive Protein As a Predictor of Prognosis in Chronic Obstructive Pulmonary Disease
Morten Dahl,
Jørgen Vestbo,
Peter Lange,
Stig E. Bojesen,
Anne Tybjærg-Hansen and
Børge G. Nordestgaard
Department of Clinical Biochemistry, Herlev University Hospital, Herlev; Department of Clinical Biochemistry, Rigshospitalet, Copenhagen University Hospital, Copenhagen; Department of Cardiology and Respiratory Medicine, Hvidovre University Hospital, Hvidovre; Copenhagen City Heart Study, Bispebjerg University Hospital, Copenhagen, Denmark; and North West Lung Centre, Wythenshawe Hospital, Manchester, United Kingdom
Correspondence and requests for reprints should be addressed to Børge G. Nordestgaard, M.D., D.M.Sc., Professor, Chief Physician, Department of Clinical Biochemistry, 54M1, Herlev University Hospital, Herlev Ringvej 75, Herlev DK-2730, Denmark. E-mail: brno{at}herlevhosp.kbhamt.dk
Rationale: Patients with chronic obstructive pulmonary disease (COPD) have an ongoing systemic inflammation, which can be assessed by measuring serum C-reactive protein (CRP).
Objective: To determine whether increased serum CRP in individuals with airway obstruction predicts future hospitalization and death from COPD.
Methods: We performed a cohort study with a median of 8-yr follow-up of 1,302 individuals with airway obstruction selected from the ongoing Copenhagen City Heart Study.
Measurements and Main Results: We measured serum CRP at baseline, and recorded COPD admissions and deaths as outcomes. During follow-up, 185 (14%) individuals were hospitalized due to COPD and 83 (6%) died of COPD. Incidences of COPD hospitalization and COPD death were increased in individuals with baseline CRP > 3 mg/L versus  3 mg/L (log rank: p < 0.001). After adjusting for sex, age, FEV1% predicted, tobacco consumption, and ischemic heart disease, the hazard ratios for hospitalization and death due to COPD were increased at 1.4 (95% confidence interval, 1.0–2.0) and 2.2 (1.2–3.9) in individuals with baseline CRP > 3 mg/L versus 3 mg/L. After close matching for FEV1% predicted and adjusting for potential confounders, baseline CRP was, on average, increased by 1.2 mg/L (analysis of variance: p = 0.002) and 4.1 mg/L (p = 0.001) in those who were subsequently hospitalized or died of COPD, respectively. The absolute 10-yr risks for COPD hospitalization and death in individuals with CRP above 3 mg/L were 54 and 57%, respectively, among those older than 70 yr with a tobacco consumption above 15 g/d and an FEV1% predicted of less than 50.
Conclusions: CRP is a strong and independent predictor of future COPD outcomes in individuals with airway obstruction.
Key Words: cohort study • lung diseases, obstructive • airway obstruction • inflammation • biological markers
| AT A GLANCE COMMENTARY
Scientific Knowledge on the Subject
C-reactive protein (CRP) has been shown to be a marker of inflammation in atherosclerosis and levels of CRP correlate with the degree of pulmonary inflammation in stable COPD.
What This Study Adds to the Field
Serum C-reactive protein is a strong long-term predictor of clinical COPD outcomes in individuals with airway obstruction.
|
This article has been cited by other articles:
|
|
|
|
 
W. T. McNicholas
Chronic Obstructive Pulmonary Disease and Obstructive Sleep Apnea: Overlaps in Pathophysiology, Systemic Inflammation, and Cardiovascular Disease
Am. J. Respir. Crit. Care Med.,
October 15, 2009;
180(8):
692 - 700.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Watz, B. Waschki, A. Kirsten, K.-C. Muller, G. Kretschmar, T. Meyer, O. Holz, and H. Magnussen
The Metabolic Syndrome in Patients With Chronic Bronchitis and COPD: Frequency and Associated Consequences for Systemic Inflammation and Physical Inactivity
Chest,
October 1, 2009;
136(4):
1039 - 1046.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. D. Sin and J. Vestbo
Biomarkers in Chronic Obstructive Pulmonary Disease
Proceedings of the ATS,
September 15, 2009;
6(6):
543 - 545.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Brusasco
Statistically significant or clinically useful? From population studies to patient care
Eur. Respir. J.,
August 1, 2009;
34(2):
291 - 292.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R P Young, R Hopkins, and T E Eaton
Potential benefits of statins on morbidity and mortality in chronic obstructive pulmonary disease: a review of the evidence
Postgrad. Med. J.,
August 1, 2009;
85(1006):
414 - 421.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Lacoma, C. Prat, F. Andreo, and J. Dominguez
Biomarkers in the management of COPD
Eur. Respir. Rev.,
June 1, 2009;
18(112):
96 - 104.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J. Barnes and B. R. Celli
Systemic manifestations and comorbidities of COPD
Eur. Respir. J.,
May 1, 2009;
33(5):
1165 - 1185.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Quarck, T. Nawrot, B. Meyns, and M. Delcroix
C-reactive protein a new predictor of adverse outcome in pulmonary arterial hypertension.
J. Am. Coll. Cardiol.,
April 7, 2009;
53(14):
1211 - 1218.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D R Taylor
Risk assessment in asthma and COPD: a potential role for biomarkers?
Thorax,
March 1, 2009;
64(3):
261 - 264.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. M.T.A. van Durme, K. M.C. Verhamme, A.-J. L.H.J. Aarnoudse, G. R. Van Pottelberge, A. Hofman, J. C.M. Witteman, G. F. Joos, G. G. Brusselle, and B. H.C. Stricker
C-Reactive Protein Levels, Haplotypes, and the Risk of Incident Chronic Obstructive Pulmonary Disease
Am. J. Respir. Crit. Care Med.,
March 1, 2009;
179(5):
375 - 382.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G Engstrom, N Segelstorm, M Ekberg-Aronsson, P M Nilsson, F Lindgarde, and C-G Lofdahl
Plasma markers of inflammation and incidence of hospitalisations for COPD: results from a population-based cohort study
Thorax,
March 1, 2009;
64(3):
211 - 215.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
B. M. Roede, P. Bresser, J. M. Prins, F. Schellevis, T. J. M. Verheij, and P. J. E. Bindels
Reduced risk of next exacerbation and mortality associated with antibiotic use in COPD
Eur. Respir. J.,
February 1, 2009;
33(2):
282 - 288.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. A. Antoniu
Systemic Inflammation and Inhaled Corticosteroids in COPD
Am. J. Respir. Crit. Care Med.,
January 15, 2009;
179(2):
170 - 170.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. D. Sin and S. F. Paul Man
Systemic Inflammation and Inhaled Corticosteroids in COPD
Am. J. Respir. Crit. Care Med.,
January 15, 2009;
179(2):
170 - 171.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Gerhardsson de Verdier
The Big Three Concept: A Way to Tackle the Health Care Crisis?
Proceedings of the ATS,
December 1, 2008;
5(8):
800 - 805.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. J. Barnes
Future Treatments for Chronic Obstructive Pulmonary Disease and Its Comorbidities
Proceedings of the ATS,
December 1, 2008;
5(8):
857 - 864.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. M Turino
COPD and biomarkers: the search goes on
Thorax,
December 1, 2008;
63(12):
1032 - 1034.
[Full Text]
[PDF]
|
|
|
|
|
|
|
D R Taylor and I D Pavord
Biomarkers in the assessment and management of airways diseases
Postgrad. Med. J.,
December 1, 2008;
84(998):
628 - 634.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Dahl, R. P. Bowler, K. Juul, J. D. Crapo, S. Levy, and B. G. Nordestgaard
Superoxide Dismutase 3 Polymorphism Associated with Reduced Lung Function in Two Large Populations
Am. J. Respir. Crit. Care Med.,
November 1, 2008;
178(9):
906 - 912.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. Stolz, M. Christ-Crain, N. G. Morgenthaler, D. Miedinger, J. Leuppi, C. Muller, R. Bingisser, J. Struck, B. Muller, and M. Tamm
Plasma Pro-Adrenomedullin But Not Plasma Pro-Endothelin Predicts Survival in Exacerbations of COPD
Chest,
August 1, 2008;
134(2):
263 - 272.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Zorzetto, E. Russi, O. Senn, M. Imboden, I. Ferrarotti, C. Tinelli, I. Campo, S. Ottaviani, R. Scabini, A. von Eckardstein, et al.
SERPINA1 Gene Variants in Individuals from the General Population with Reduced {alpha}1-Antitrypsin Concentrations
Clin. Chem.,
August 1, 2008;
54(8):
1331 - 1338.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. D. Sin and S. F. P. Man
Biomarkers in COPD: Are We There Yet?
Chest,
June 1, 2008;
133(6):
1296 - 1298.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Dahl
Biomarkers for Chronic Obstructive Pulmonary Disease: Surfactant Protein D and C-Reactive Protein
Am. J. Respir. Crit. Care Med.,
June 1, 2008;
177(11):
1177 - 1178.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. P. de Torres, V. Pinto-Plata, C. Casanova, H. Mullerova, E. Cordoba-Lanus, M. Muros de Fuentes, A. Aguirre-Jaime, and B. R. Celli
C-Reactive Protein Levels and Survival in Patients With Moderate to Very Severe COPD
Chest,
June 1, 2008;
133(6):
1336 - 1343.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. D. Sin, S. F. P. Man, D. D. Marciniuk, G. Ford, M. FitzGerald, E. Wong, E. York, R. R. Mainra, W. Ramesh, L. S. Melenka, et al.
The Effects of Fluticasone with or without Salmeterol on Systemic Biomarkers of Inflammation in Chronic Obstructive Pulmonary Disease
Am. J. Respir. Crit. Care Med.,
June 1, 2008;
177(11):
1207 - 1214.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Kim, T. J. Rogers, and G. J. Criner
New Concepts in the Pathobiology of Chronic Obstructive Pulmonary Disease
Proceedings of the ATS,
May 1, 2008;
5(4):
478 - 485.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Falk, O. A. Minai, and Z. Mosenifar
Inhaled and Systemic Corticosteroids in Chronic Obstructive Pulmonary Disease
Proceedings of the ATS,
May 1, 2008;
5(4):
506 - 512.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. A. Falk, S. Kadiev, G. J. Criner, S. M. Scharf, O. A. Minai, and P. Diaz
Cardiac Disease in Chronic Obstructive Pulmonary Disease
Proceedings of the ATS,
May 1, 2008;
5(4):
543 - 548.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. MacNee
Update in Chronic Obstructive Pulmonary Disease 2007
Am. J. Respir. Crit. Care Med.,
April 15, 2008;
177(8):
820 - 829.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Watz, B. Waschki, C. Boehme, M. Claussen, T. Meyer, and H. Magnussen
Extrapulmonary Effects of Chronic Obstructive Pulmonary Disease on Physical Activity: A Cross-sectional Study
Am. J. Respir. Crit. Care Med.,
April 1, 2008;
177(7):
743 - 751.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Koenig, N. Khuseyinova, J. Baumert, and C. Meisinger
Prospective Study of High-Sensitivity C-Reactive Protein as a Determinant of Mortality: Results from the MONICA/KORA Augsburg Cohort Study, 1984-1998
Clin. Chem.,
February 1, 2008;
54(2):
335 - 342.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. K. Han, V. V. McLaughlin, G. J. Criner, and F. J. Martinez
Pulmonary Diseases and the Heart
Circulation,
December 18, 2007;
116(25):
2992 - 3005.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Viegi, F. Pistelli, D. L. Sherrill, S. Maio, S. Baldacci, and L. Carrozzi
Definition, epidemiology and natural history of COPD
Eur. Respir. J.,
November 1, 2007;
30(5):
993 - 1013.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. E. Alexeeff, A. A. Litonjua, D. Sparrow, P. S. Vokonas, and J. Schwartz
Statin Use Reduces Decline in Lung Function: VA Normative Aging Study
Am. J. Respir. Crit. Care Med.,
October 15, 2007;
176(8):
742 - 747.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R A Stockley
Biomarkers in COPD: time for a deep breath
Thorax,
August 1, 2007;
62(8):
657 - 660.
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. F. Rabe, B. Beghe, F. Luppi, and L. M. Fabbri
Update in Chronic Obstructive Pulmonary Disease 2006
Am. J. Respir. Crit. Care Med.,
June 15, 2007;
175(12):
1222 - 1232.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Vestbo
Systemic inflammation and progression of COPD
Thorax,
June 1, 2007;
62(6):
469 - 470.
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. C. Donaldson
C-reactive Protein: Does It Predict Mortality?
Am. J. Respir. Crit. Care Med.,
February 1, 2007;
175(3):
209 - 210.
[Full Text]
[PDF]
|
|
|
Copyright © 2007 American Thoracic Society
|
|
|
